NVS · Novartis AG
$156.11
+2.40% last session
End-of-day data · updated 2026-07-29
Market cap
$304B
Enterprise value
$346B
Trailing P/E
24.2
Forward P/E
16.2
Dividend yield
3.0%
Beta
0.50
Avg volume
2M
Employees
75K
2D change
2.40%
5D change
—
10D change
3.96%
30D change
1.43%
60D change
6.45%
MTD change
3.70%
YTD change
19.47%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NVS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-03-26
Latest call per bank · past 12 months
Morgan Stanley
Overweight$170
+8.9% vs priceBarclays
Equal-Weight$0.00
-100.0% vs priceJP Morgan
Overweight$0.00
-100.0% vs priceGoldman Sachs
Sell$118
-24.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-03-26 | Morgan Stanley | Maintains | Overweight | $143 → $170 |
| 2026-01-06 | Barclays | Upgrade | Underweight → Equal-Weight | $0.00 |
| 2025-12-08 | JP Morgan | Upgrade | Neutral → Overweight | $0.00 |
| 2025-09-12 | Goldman Sachs | Downgrade | Neutral → Sell | $119 → $118 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 61 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 5.2% above the 50-day MA ($151.94).
- Price vs 200-day MA: Trading 11.3% above the 200-day MA ($143.55).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.37) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($163.64).
NVS Price Chart
Loading chart for NVS…
Fundamentals
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
More in Drug Manufacturers - General
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.